Morphotek, Inc.

Genaera Corporation

The Johns Hopkins University

Eisai Inc.

Other

Magainin Pharmaceuticals, Inc.

Ligand Pharmaceuticals, Inc.

Navrogen, Inc.

Vogelstein, Bert

Grasso, Luigi

Sass, Philip, M.

Nicolaides, Nicholas, C.

Kinzler, Kenneth

Nicholas C Nicolaides

Luigi Grasso

Philip M Sass

Roy Clifford Levitt

Bert Vogelstein

Kenneth W Kinzler

Yuhong Zhou

Wolfgang Ebel

Eric Routhier

Kenneth J Holroyd

W Lee Maloy

Tao Sai

Mike McLane

Marc Berger

Jian Li

Qimin Chao

Steve Jones

Brian Tomkowicz

Jamila Louahed

U Prasad Kari

Qu Dong

Daniel John O'Shannessy

Elizabeth B Somers

Shaohong Liang

Phillip M Sass

Craig A Rosen

Steven M Ruben

Mark D Adams

William Alvin Kinney

Nickolas Papadopoulos

Ying-Fei Wei

Claire M Fraser

William A Haseltine

Ewen F Kirkness

Robert D Fleischmann

Rebecca A Fuldner

Howard Sands

Michael McLane

Ken Kinzler

J Bradford Kline

Brian E Tomkowicz

Using protein structural probes one can identify tumor-induced or -produced (TIPS) factors that bind to therapeutic antibodies and change their dynamic structure, thereby negatively affecting their humoral immune functions as well as their pharmacologic activity. Using such protein structural probes and TIPS factors one can screen and identify inhibitors that can counter the binding of TIPS factors to affected therapeutic antibodies. These inhibitors can be used in the presence of a TIPS factor-susceptible antibody (TSA) for treating cancer. An inhibitor can be used alone or in combination with chemotherapy for treating cancer. Patients can be screened to identify those with low or no TIPS factor production as candidates for antibody therapy even in the case in which the antibody is a TSA. Conversely, those with high TIPS factor production are candidates for inhibitor therapy.

Composition and methods for measuring antibody dynamics

Provided herein are methods for determining the risk that a subject diagnosed with colorectal cancer will develop a recurrence of colorectal cancer and methods of predicting clinical outcome for a subject diagnosed with colorectal cancer by a) determining the level of expression for each marker of a panel of markers in a panel of tumor compartments in a tumor tissue sample from the subject, wherein the panel of markers comprises at least two of TEM1, HIF2&#x3b1;, CAIX, PDGFR&#x3b2;, fibronectin, collagen I, collagen IV, and CD31 and wherein the panel of tumor compartments comprises at least three tumor compartments of pure stroma, tumor, stromal vessel, and tumor vessel; b) determining the TAPPS score for said subject; and c) comparing the TAPPS score of the subject to the TAPPS score of a population of subjects diagnosed with colorectal cancer. Also provided are related computer-implemented methods and systems, kits, and tumor microarrays.

Methods for determining prognosis of colorectal cancer

This invention relates to novel monoclonal antibodies that specifically bind to the alpha-folate receptor. In some embodiments, the antibodies inhibit a biological activity of folate receptor-&#x3b1; (FR-&#x3b1;). The antibodies are useful in the treatment of certain cancers, particularly cancers that have increased cell surface expression of the alpha-folate receptor ('FR-&#x3b1;'), such as ovarian, breast, renal, colorectal, lung, endometrial, or brain cancer. The invention also relates to cells expressing the monoclonal antibodies, antibody derivatives, such as chimeric and humanized monoclonal antibodies, antibody fragments, and methods of detecting and treating cancer using the antibodies, derivatives, and fragments.

Monoclonal antibodies that specifically block biological activity of a tumor antigen

Provided herein are antibodies that specifically bind and neutralizeenterotoxin B. In addition, nucleic acids encoding such antibodies, and cells that express such antibodies are provided. Also provided are methods for treating diseases mediated by, and for neutralizingenterotoxin B.

High affinity antibodies that neutralizeenterotoxin B

This invention relates to the use of monoclonal and polyclonal antibodies that specifically bind to and have the ability in the alternative to become internalized by cells expressing folate receptor alpha (FRA) and to induce an immune effector activity such as antibody-dependent cellular cytotoxicity. The antibodies are useful in specific delivery of pharmacologic agents to FRA-expressing cells as well as in eliciting an immune-effector activity particularly on tumor cells and precursors. The invention is also related to nucleotides encoding the antibodies of the invention, cells expressing the antibodies; methods of detecting cancer cells; and methods of treating cancer using the antibodies.

Antibodies with immune effector activity and that internalize in folate receptor alpha-positive cells

The invention provides methods for inhibiting the interaction of endosialin with endosialin ligands. The inhibition is effectuated on the genetic level, by inhibiting endosialin gene expression, and on the protein level, by blocking the interaction of cell-surface expressed endosialin with ligands such as fibronectin and collagen. The invention provides methods for identifying inhibitors of the interaction of endosialin with endosialin ligands. Also provided are methods for inhibiting angiogenesis and neovascularization in vivo and in vitro.

Methods for inhibiting the binding of endosialin to ligands

Hybridoma lines that secrete human monoclonal antibodies with high binding specificity and biological activity, particularly neutralizing activity against granulocyte-macrophage colony stimulating factor, and methods of generating the hybridoma lines are provided. Target antigens and epitopes are also provided. The antibodies may be used in therapeutic methods, for example in the treatment of cancer, infectious disease, or autoimmune disease.

Antigenic GM-CSF peptides and antibodies to GM-CSF

[object Object]

Growing community of inventors

Boothwyn, PA, United States of America

Nicholas C Nicolaides